Haleon plc (HLN) AI Stock Analysis

Haleon plc specializes in researching, developing, manufacturing, and distributing consumer healthcare products. Established in 2021 as DRVW 2022 plc and rebranded in February 2022, the company offers therapeutic oral health, pain relief, respiratory health, digestive health, and vitamins, minerals, and supplements. Its geographic reach includes North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company's portfolio features widely recognized household brands such as Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum.

Haleon's five-year revenue compound annual growth rate from FY2020 to FY2025 was 2.2%. Annual revenue peaked at $11.30B in FY2023 before declining 0.6% to $11.23B in FY2024 and falling 1.8% to $11.03B in FY2025. Despite top-line contraction, profitability expanded, with gross margin rising from 60.6% in FY2022 to 63.3% in FY2025, and operating margin widening from 16.8% in FY2022 to 21.9% in FY2025. Annual net income grew to $1.63B in FY2025. In the trailing twelve months ended June 30, 2026, revenue stood at $11.15B with an operating margin of 23.9%. In the latest quarter ended June 30, 2026, quarterly revenue grew 2.2% year-over-year, while quarterly earnings fell 4.5%.

As of June 30, 2026, Haleon held $821.0M in cash and short-term investments against total debt of $8.20B, resulting in net debt of $7.38B. Total assets were $32.38B, shareholders' equity was $16.28B, and the current ratio was 0.69, alongside a debt-to-equity ratio of 0.50. In FY2025, operating cash flow was $2.29B and free cash flow was $1.97B. Capital allocation in FY2025 included capital expenditures of $314.9M, share buybacks of $639.7M, and dividends paid of $598.6M.

At a last close of $10.13, Haleon holds a market cap of $44.55B and an enterprise value of $50.18B. Its trailing P/E of 20.7x and forward P/E of 15.7x trade below the median of its US-listed Healthcare peers at 24.6x and 17.3x, respectively. The stock's price-to-sales multiple is 4.0x compared to the peer median of 4.1x, while its EV/EBITDA of 13.4x is above the peer median of 12.0x. Over the past year, Haleon returned 12.3%, trailing the S&P 500 return of 16.8%.

Haleon pays a semiannual dividend with an annualized forward rate of $0.20 per share, representing a dividend yield of 1.96%. The payout ratio is 1.6%, and the company has paid dividends for 4 consecutive years. Its most recent ex-dividend date was August 14, 2026.

Wall Street coverage includes 1 Strong Buy, 2 Buy, and 2 Hold ratings, with no Sell or Strong Sell recommendations. The mean price target is $11.93, indicating 17.8% upside relative to the last close of $10.13. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $11.39B and EPS of $0.56, representing 11.0% EPS growth. Haleon beat EPS estimates in 1 of the last 4 quarters, and its next earnings date is October 29, 2026.

This page is an AI-written research summary of Haleon plc (HLN). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: HLN income statement, HLN balance sheet, HLN key metrics, HLN analyst forecast, HLN chart. See the HLN stock overview for the latest quote and news.